English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 905079      Online Users : 840
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14250


    Title: Compassionate treatment of brainstem tumors with boron neutron capture therapy: A case series
    Authors: Chen, YW;Lee, YY;Lin, CF;Huang, TY;Ke, SH;Mu, PF;Pan, PS;Chen, JK;Lan, TL;Hsu, PC;Liang, ML;Chen, HH;Chang, FC;Wu, CC;Lin, SC;Lee, JC;Chen, SK;Liu, HM;Peir, JJ;Tsai, HY;Lin, KH;Peng, NJ;Chen, KH;Wu, YH;Kang, YM;Yang, WC;Liou, SC;Huang, WH;Tanaka, H;Wong, TT;Chao, Y;Chou, FI
    Contributors: Institute of Biomedical Engineering and Nanomedicine
    Abstract: Brainstem tumors are heterogenous and cancerous glioma tumors arising from the midbrain, pons, and the medulla that are relatively common in children, accounting for 10% to 20% of all pediatric brain tumors. However, the prognosis of aggressive brainstem gliomas remains extremely poor despite aggressive treatment with chemotherapy and radiotherapy. That means there are many life-threatening patients who have exhausted all available treatment options and are beginning to face end-of-life stage. Therefore, the unique properties of highly selective heavy particle irradiation with boron neutron capture therapy (BNCT) may be well suited to prolong the lives of patients with end-stage brainstem gliomas. Herein, we report a case series of life-threatening patients with end-stage brainstem glioma who eligible for Emergency and Compassionate Use, in whom we performed a scheduled two fractions of salvage BNCT strategy with low treatment dosage each time. No patients experienced acute or late adverse events related to BNCT. There were 3 patients who relapsed after two fractionated BNCT treatment, characterized by younger age, lower T/N ratio, and receiving lower treatment dose. Therefore, two fractionated low-dose BNCT may be a promising treatment for end-stage brainstem tumors. For younger patients with low T/N ratios, more fractionated low-dose BNCT should be considered.
    Date: 2022-04-10
    Relation: Life-Basel. 2022 Apr 10;12(4):Article number 566.
    Link to: http://dx.doi.org/10.3390/life12040566
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2075-1729&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000785658700001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85129084036
    Appears in Collections:[陳仁焜] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ISI000785658700001.pdf1992KbAdobe PDF152View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback